The natural anti-Gal antibody constitutes 1 % of circulating IgG in humans and interacts specifically with the carbohydrate epitope Gala1 -3Ga1@1-4GlcNAc-R (the a-galactosyl epitope). In view of the unusually large amounts of this antibody in the serum, it was of interest to determine the proportion of circulating B lymphocytes capable of synthesizing anti-Gal. For this purpose, blood B lymphocytes were incubated with Epstein-Barr virus (EBV) and plated in microtiter wells. Proliferation of the EBV transformed B lymphocytes was readily visible after 3 weeks of incubation. The supernatants from wells containing proliferating B-lymphoid clones were assayed for anti-Gal by an agglutination assay with rabbit red blood cells and the specificity of the agglutinating antibodies was further confirmed by their interaction with synthetic oligosaccharides and by enzyme-linked immunosorbent assay with glycoproteins. Approximately 5% of the wells contained anti-Gal antibodies. Limiting dilution studies and IgH gene rearrangement NE OF THE HALLMARKS of the immune system is 0 its great diversity in the response to various antigens.
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It has been estimated that B lymphocytes are capable of producing antibodies against more than 1 million different antigens.'s2 In view of this antibody diversity, it was surprising to find that anti-Gal constitutes as much as 1 % of circulating IgG in human ~e r u m .~-~ Anti-Gal is a natural antibody found in all h u m a n~.~ It interacts specifically with mammalian glycoproteins and glycolipids expressing the carbohydrate epitope Gala 1 -3Galb 1 -4GlcNAc-R (termed the a-galactosyl epitope).6-" Glycolipids or glycoproteins with carbohydrate chains other than the a-galactosyl epitope (eg, globoside, paragloboside, ganglioside GM3, Forssman antigen, blood groups A and B antigens, bovine fetuin, human thyroglobulin, and human laminin) do not interact with anti-Gal, indicating that this natural antibody is highly specific for the a-galactosyl epitope and is not a polyreactive antib~dy.','~.'' Anti-Gal is produced throughout life as a polyclonal antibody (ie, it can be detected as multibands in preparative isoelectrofocusing gel),3 presumably in response to antigenic stimulation by gastrointestinal bacteria, many of which express carbohydrate structures similar to the agalactosyl epit~pe.'~,'' Anti-Gal is found only in Old World monkeys, apes, and humans. Nonprimate mammals, prosimians, and New World monkeys do not produce this antibody because their cells express an abundance of a-galactosyl epitopes (>lo6 epitopes per cell) on membrane glycolipids and glycoproteins, thus they are immunotolerant to this carbohydrate e p i t~p e . '~~'~ Isolation of anti-Gal from normal human sera by affinity chromatography results in yields of 30 to 100 pg IgG/mL serum (ie, approximately 1 % of circulating IgG).3-s3'6 AntiGal concentration in serum is 500-fold higher than that of natural antibodies to proteins such as anti-cytoskeletal proteins'' or anti-band 3 antibodies." In addition, production of anti-Gal may markedly increase above the normal level in the first trimester of pregnancy,I6 in the serum of patients with a variety of autoimmune diseases, including Graves' disease," scleroderma,20 Henoch-Schonlein p~r p u r a ,~ some patterns suggested that each well contained an average of five proliferating B-lymphoid clones. Thus, it is concluded that approximately 1 %of circulating B lymphocytes are capable of producing anti-Gal. The proportion of anti-Galproducing lymphoid clones exceeds by fourfold that of clones producing anti-blood group A or anti-blood group B antibodies. Individual anti-Gal clones display fine variations in their combining site, as indicated by their differential interaction with a-galactosyl epitopes on glycolipids and on N-linked carbohydrate chains of glycoproteins. The high frequency of precursor B lymphocytes capable of producing anti-Gal, found in every individual and the restricted specificity of this antibody to a-galactosyl epitopes, potentially makes anti-Gal-producing lymphocytes an effective system for studying human lg genes involved in the natural immune response to structurally defined haptens. Because anti-Gal is synthesized in large amounts in humans, we hypothesized that this natural anti-carbohydrate antibody is produced by a large proportion of B lymphocytes. We studied this hypothesis by determining the proportion of Epstein-Barr virus (EBV)-transformed circulating B lymphocytes that produce anti-Gal and assessed in parallel anti-blood group A or B antibody-producing lymphocytes, as specificity controls. EBV immortalizes mature human B lymphocytes in a nonselective and induces Ig secretion by these transformed ~e l l s .~~-~~ Immortalized B-lymphoid clones were grown in microtiter wells and screened for anti-Gal production by an agglutination assay with rabbit red blood cells (RBC),3-s because the a-galactosyl epitope is the major carbohydrate structure on these RBC.28"0 In parallel, the immortalized clones were screened for production of anti-blood group A and anti-blood group B antibodies by agglutination of human RBC expressing the corresponding blood group antigens. Calculations based on the proportion of microtiter wells containing anti-Gal antibodies and on the average number of lymphoidclones proliferating in each well, indicate that as many as 1% of circulating B lymphocytes are capable of producing the natural anti-Gal antibody and 0.25% of circulating B lymphocytes are capable of producing anti-A or anti-B antibodies. Fine variations in the combining site of individual anti-Gal producing clones were determined by their differential interaction with a-galactosyl epitopes on glycolipids and glycoproteins. The EBV concentration in the supernatant of the B95.8 cells was high enough to induce B-lymphocyte transformation even at a dilution of 1: 100 ofthe supernatant, indicating that virus concentration was not a limiting factor in the transformation process. Aliquots of 0.2 mL were placed in flat bottom wells of four plates each of 96 wells (ie, 50,000 cells per well). The cells were fed every 4 days by replacing 0.1 mL of supernatant. The plates were incubated for 23 days at 37"C, in 5% CO, humidified atmosphere. The wells were examined by microscopy for evidence of lymphoid proliferation, ie, the presence of characteristic clumps of proliferating cells', and acidification of the medium. Transformed lymphoid cells were found to be growing in more than 90% of the wells. The supernatants were removed and assayed for anti-Gal and for anti-blood group A and B antibodies (Table 1) .
MATERIALS AND METHODS

Peripheral
Hemagglutination assays. The supernatants were assayed for anti-Gal and anti-blood group A and B antibodies by hemagglutination assays using rabbit antihuman Ig (anti-IgG, IgM, and IgA antibodies) (Dako, Copenhagen, Denmark) as secondary antibody. Fifty-microliter aliquots of supernatants and 1O-pl aliquots of Transformation of human B lymphocytes by EBV. washed rabbit RBC (10% vol/vol) were mixed in V-shaped microtiter wells to test for anti-Gal activity as previously de~cribed.~-'The a-galactosyl epitope is the most abundant carbohydrate epitope on rabbit RBC,28-30 therefore, these RBC readily bind anti-Ga1.3.6,7 After a 30 minute incubation at room temperature, the plates were washed three times with 0. I mL phosphate-buffered saline (PBS), by spinning the plates at 1,000 rpm in a table top Beckman centrifuge, removing the supernatant, and resuspending the RBC in PBS. Subsequently, the pelleted RBC were resuspended in rabbit antihuman Ig diluted 1: 1 ,OOO in PBS. Hemagglutination was scored after 60 minutes of incubation at room temperature, as RBC carpets formed in the wells.' Anti-blood group A and anti-blood group B antibody production was scored with supernatants from the same cultures. The hemagglutination assays were performed with human blood group A or blood group B RBC. The assay steps were similar to those in the anti-Gal assay, using the same concentration of the secondary antibody (Table 2) .
Galal-3Galpl-4GlcNAc-R specijicity of rabbit RBC agglutinating antibodies. To confirm the anti-Gal specificity (ie, interaction with Gala 1-3GalBI -4GlcNAc-R epitopes) of antibody clones that agglutinate rabbit RBC, the antibodies from various clones of different individuals were subjected to adsorption on solid-phase synthetic oligosaccharides, as previously desc~ibed.~.~'.'~ For this purpose, the cell cultures from the positive wells were expanded to 50 mL. Ten-milliliter supernatant aliquots from each of these eight cell cultures were chromatographed on 1 mL silica bead columns (Synsorb, Chembiomed, Edmonton, Alberta.. Canada) to which various synthetic carbohydrate epitopes were linked ( Titer of anti-Gal as assayed by rabbit RBC agglutination. t Five milliliters of human serum were loaded on each column.
quently, the columns were washed with PBS; the bound antibodies eluted with 1 mL cold glycine HC1 buffer (pH 2.8) and immediately neutralized with 0.1 N NaOH. The eluates from the various columns were then assayed for agglutination of rabbit RBC. Determination of anti-Gal concentration was performed in four of the antiGal producing cultures by passing 100 mL of supernatant through the Gala 1-3GalPl-4GlcNAc-R column, acid elution ofbound antibody, and assessment of its concentration by absorption at 280 nm.
Enzyme-linked immunoabsorbent assays (ELISA). An ELISA
assay was performed to identify the Ig class of in vitro produced anti-Gal clones. The Gala 1 -3GalP 1 -4GlcNAc-R Synsorb beads were used as a solid-phase antigen, and alkaline phosphatase-linked specific rabbit anti-human IgG, IgM, or IgA antibodies (Dako) were used as secondary antibodies. The color reaction was obtained with the alkaline phosphatase reagent (p-nitrophenylphosphate, Sigma) and absorbance was measured at 405 nm.
Mouse laminin" and rabbit ceramide pentahexoside (CPH)" were used as solid-phase antigens expressing a-galactosyl epitopes for determining minor variations in specificities of the in vitro produced anti-Gal clones. Plates were coated with 1 pg of CPH obtained from rabbit RBC6s7 or with 30 pg/mL of laminin (Sigma) as previously described." The glycoprotein bovine fetuin, which was previously ~h o w n~~, '~ to have three 0-linked and three N-linked carbohydrate chains, all of which have terminal sialic acid units, was used as specificity control for the antibody interaction with a-galactosyl epitopes on mouse laminin. After blocking with 1% bovine serum albumin (BSA) in PBS, 0.2 mL aliquots ofthe various monoclonal anti-Gal antibodies were placed in the wells in triplicates. After 2 hours of incubation at 24"C, the wells were washed with PBS containing 0.05% Tween and secondary rabbit antihuman IgG, IgM, or IgA antibodies conjugated to alkaline phosphatase (Dako) diluted 1: 1,000 were added to the wells. After 1 hour of incubation, the wells were washed, and the binding ofthe secondary antibody was determined as described above.
Assessment of the number ofproliferating B-lymphoid clones per well. Two approaches were used to assess the number of transformed B-lymphoid clones that proliferated in each well. (1) Limiting dilution: The assay was performed with a slight modification of previous studies by Taub et alZ7 and Tosato et Non-T PBMC exposed to EBV were plated at different numbers per well and the proportion of wells containing immortalized B-lymphoid clones was determined visually after 23 days of incubation, using an inverted microscope. As indicated above, wells containing immortalized proliferating B lymphocytes were readily identified as containing characteristic clumps of proliferating lymphoid cells,'' which ultimately cause acidification of the medium. It was assumed that the plate with the lowest number of cells per well that yielded proliferating lymphoid cells in most (>80%) of the wells contained an average of one clone per well. The number of clones developing from 5 X lo4 plated non-T PBMC per well was calculated from the ratio between 50,000 and the number of cells needed for the growth of one clone per well. (2) Heavy chain gene rearrangement pattern: Because both alleles in B lymphocytes undergo VDJ and DJ rearrangement, we assumed that the number of lymphoid clones proliferating in each well may be assessed by the number of bands observed in Southern blot hybridization with a probe for the J region of the IgH locus. This method has been used in the diagnosis of B lymphomas and leukemias where the malignant cells, being monoclonal, have rearranged Ig genes, which appear as distinct bands in Southern blot hybridization with a JH p r~b e .~' ,~~ Cells from individual wells of different donors were expanded to approximately 3 X lo7 cells in tissue culture. The DNA was extracted from the cells and digested with the restriction enzymes Hind111 and BamHI. Subsequently, the cleaved DNA was subjected to electrophoresis and Southern blot hybridization38939 with the J, probe purchased from Oncogene Science (Uniondale, NY).
RESULTS
Proportion of wells containing anti-Gal, anti-blood group
A, and anti-blood group B producing lymphoid clones.
Human non-T PBMC were incubated overnight with EBV containing medium and subsequently plated in four 96-well plates ( 5 X lo4 cells/well). After 23 days, more than 90% of the wells contained proliferating transformed B lymphocytes. The supernatants from these wells were removed and assayed for agglutination of RBC expressing one of the three carbohydrate epitopes listed in Table 1 . On the average, 5% of the wells were found to contain antibodies agglutinating rabbit RBC (Table 2) , ie, anti-Gal antib~dies.~ The specificity of these antibodies for the Gala 1 -3GalBl-4GlcNAc-R epitope was further confirmed by adsorption assays on solid-phase oligosaccharides and in ELISA, as described below. The production of anti-blood group A and anti-blood group B antibodies was also assayed in the same supernatants by agglutination with the corresponding A or B RBC. In the individual donors, the proportion of anti-Gal containing wells was found t o be threefold to 1 1-fold higher than the proportion of wells containing anti-blood group A or anti-blood group B antibodies ( Table 2) 
causing the agglutination of A or B RBC were specific to the epitopes listed in Table I and did not interact with undefined RBC antigens because none ofthese antibodies agglutinated both types of human RBC. It is also of interest to note that there were no antibodies to self blood group antigens in any of the wells, ie, no anti-A produced in wells with transformed lymphocytes from blood groups A individuals and no anti-B produced by cells of blood group B individuals. In addition, none of the supernatants that agglutinated rabbit RBC, displayed agglutinating activity with A or B RBC.
Gakal-3Galfil-4GlcNAc-R specijicity of the in vitro produced anti-Gal antibodies. The a-galactosyl epitope is the major carbohydrate epitope on rabbit RBC,28-30 and more than 95% of the antibodies in human serum that agglutinate rabbit RBC are directed against the anti-Gal m~i e t y .~.~,~ However, it could be argued that the hemagglutinatingactivity of antibodies produced by some of the transformed Blymphoid clones is directed against rabbit RBC epitopes other than the a-galactosyl epitope. To investigate this possibility, lymphoid cultures from 50 anti-Gal positive wells of different individuals were expanded to 50 mL cultures, containing approximately 5 X lo5 cells/mL. The agglutinating activity with rabbit RBC was maintained in only eight cultures after this expansion process. A similar loss of antibody secretion by EBV-transformed lymphocytes was previously observed in many studies attempting to produce large amounts of human monoclonal antibodies2' The supernatants from these eight cultures were subjected to affinity chromatography on silica (Synsorb) columns with various synthetic oligosaccharides ( Table 3 ). The interaction of the antibodies with these oligosaccharides was subsequently assessed by elution and determination of the eluate agglutinating activity with rabbit RBC. In the eight supernatants studied, the eluates from the Gala 1 -3Galb 1 -4GlcNAc-R (a-galactosyl epitope) column readily agglutinated rabbit RBC at titers of 1 :4 to 1 :64 (Table 3) . However, no agglutinating antibodies bound to N-acetyllactosamine, N-acetylglucosamine, blood group H, or blood group T oligosaccharides. This binding specificity was similar to that of anti-Gal from normal human serum ( Table 3 ), indicating that the in vitro produced antibodies are indeed anti-Gal clones that interact specifically with the a-galactosyl epitope.
Clones 2,6,7, and 8 were further assayed for the concentration of the monoclonal anti-Gal in the supernatant. This was accomplished by chromotography of 100 mL supernatant on the Gala l -3GalP l -4GlcNAc-R Synsorb column, washing of the column, acid elution of the bound antibody, and determination of absorbance at 280 nm. A similar procedure was performed with control medium containing only 10% FCS. The absorbance observed in the eluate ofthe control medium, and which probably resulted from marginal nonspecific binding of FCS proteins to the silica beads, was subtracted from the optical density units (OD) obtained with the eluates from each of the monoclonal antibodies. This assay indicated that anti-Gal concentration in the four supernatants was 3,4, 2, and 6 pg/mL, respectively.
Because some of the monoclonal antibodies obtained from EBV transformed lymphocytes, in particular those from CD5+ B lymphocytes, are known to be polyreactive (ie, to interact with several protein~),~~,"O it was of interest to determine whether monoclonal anti-Gal interacts with proteins lacking a-galactosyl epitopes. This was studied by subjecting the four affinity-purified eluates to ELISA with the mouse basement membrane glycoprotein, laminin (a molecule expressing 50 to 70 a-galactosyl e p i t~p e s )~~ and with bovine fetuin, which is devoid of a-galactosyl e p i t o p e~.~~.~~ As seen in Fig I , anti-Gal from all four clones readily bound to mouse laminin; however, no binding was observed in wells containing fetuin. Similarly, no binding was observed in control wells blocked with 1% BSA, further demonstrating the defined specificity of the anti-Gal clones to a-galactosyl epitopes. A similar specificity was previously observed with anti-Gal purified from normal sera." It was noted that clones 2,7, and 8 interacted with enzyme-linked rabbit antihuman IgM antibodies, whereas, clone 6 interacted with anti-IgG antibodies. No binding was observed with rabbit antihuman IgA antibodies. ELISA assays with Gala 1 -3Galfil-4GlcNAc-R Synsorb as a solidphase antigen were performed to determine the isotypes of the anti-Gal antibody clones produced by the EBV-immortalized B lymphocytes. Anti-Gal antibodies were allowed to interact with a-galactosyl epitopes on 10 mg Synsorb beads previously blocked with 1% BSA in PBS. Subsequently, the beads were washed and divided into three suspensions, incubated with class-specific, enzyme-linked rabbit antihuman IgG, IgM, or IgA antibodies, washed to remove unbound secondary antibody, and subjected to a color reaction. Four of the eight clones described in Table 3 (clones 1, 3, 5, and 6) were of IgG class, and the other four clones 2, 4, 7, and 8 were of IgM class (not shown). No IgA anti-Gal reactivity was observed.
Although the primary specificity of the various anti-Gal clones
Isotypes of the in vitro produced anti-Gal clones.
Minor variations in specijicity of anti-Gal clones. Table 3 ).
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produced in vitro was to a-galactosyl epitopes, these monoclonal antibodies displayed variations in binding capacity to the a-galactosyl epitope when it was part of a glycolipid or a glycoprotein molecule. This was determined in an ELISA assay using two solid-phase antigens with a-galactosyl epitopes: the glycolipid molecule ceramide pentahexoside (CPH) with the structure Gala 1-3Galal-4GlcNAc~l-3Galo 1 -4Gl~-Cer,6.~ and mouse laminin. The supernatants of seven anti-Gal producing clones were assayed for binding to the two antigens. As seen in Fig 2 serum anti-Gal readily bound to the glycolipid, as well as to the glycoprotein molecules. Similarly, clone 2 of anti-Gal bound to both antigens. However, anti-Gal clones 1, 3, and 4 interacted only with the glycolipid CPH, whereas clones 5 6 , and 7 bound only to laminin.
Parallel ELISA assays were performed with the glycolipid paragloboside with the structure Gala 1 -4GlcNAcD 1 -3GalDl-4Glc-Cer (ie, a structure similar to CPH, but lacking the terminal a-galactosyl residue). No binding was observed with this glycolipid, further demonstrating the a-galactosyl specificity of the anti-Gal clones.
Number of B-lymphoid clones per well. The finding that on average 5% of the wells contained anti-Gal antibodies suggested that a considerable proportion of human circulating B lymphocytes are capable of producing this antibody. To determine the actual proportion of B lymphocytes producing anti-Gal, it was necessary to have an estimate on the average number oftransformed B-lymphoid clones that proliferated in each microtiter well. Limiting dilution experiments were performed to assess the number of non-T PBMC needed to be plated in each well to generate one proliferating B-lymphoid clone per well. Determination of this number should provide an estimate of the number of transformed clones that would proliferate among 50,000 cells plated per well. Non-T PBMC were plated in 96-well plates at various numbers of cells per well subsequent to overnight incubation with EBV. The proportion of wells containing proliferating, transformed B lymphocytes was visually determined after 23 days of incubation. As shown in Fig 3, the plates with 50,000,25,000, and 12,500 cells per well contain proliferating lymphoid clones in more than 80% of the wells, indicating that in these three plates there was at least one clone per well. However, plating 6,250 cells per well resulted in lymphoid clone proliferation in approximately 50% of the wells, implying that under such conditions there was less than one proliferating clone per well. We and others24 found that the non-T PBMC fraction contains approximately 20% B lymphocytes. The limiting dilution studies suggest therefore, that approximately 1 of 2,000 plated B lymphocytes undergoes immortalization and successful proliferation under the conditions used in this study. Thus, the average number of clones developing from 50,000 cells is five. This finding is in accord with previous observations by Taub et al,27 who also reported that the transforming efficiency of EBV from B95.8 cell line supernatants is in the order of one in 10,000 plated non-T PBMC.
Another approach for estimating the average number of proliferating clones per well is based on the fact that a monoclonal population of B lymphocytes is characterized by a specific rearrangement pattern of the Ig genes. The rearrangement pattern of the heavy chain Ig genes was determined by Southern blot hybridization with a probe for the JH region of the Ig ~O C U S .~~,~~ Thus, we assumed that in an oligoclonal population, the number of clones can be estimated by the number of rearranged bands in such a Southern blot hybridization. Proliferating clones from individual wells of various donors were expanded, the DNA was then extracted and digested with the restriction enzymes BamHI and HindIII. Subsequently, DNA samples were subjected to Southern blot analysis using a portion of the human JH region as a probe. Four representative patterns of IgH gene rearrangement out of 15 different cell suspensions studied are presented in Fig 4, lanes 4 senting the unrearranged germline band of the human IgH locus DNA (Fig 4, lane I) . A similar size of the unrearranged DNA was reported by Ravetch et aL4' The hybridization of the JH probe to the DNA obtained from a polyclonal population of EBV transformed B lymphocytes yielded a smear of many bands (lane 2) resulting from the many distinct rearranged Iggenes. In a monoclonal population of EBV transformed B lymphocytes, which was grown from a single cell. two bands of the two rearranged VH genes were observed (lane 3). The lymphoid populations grown from wells of various donors (lanes 4 through 7) displayed an oligoclonal rather than polyclonal growth pattern, with 2 to IO rearrangement bands. This suggests that, although the number of clones varied in different wells, it was in the order of five per well. each clone exhibiting two rearranged Ig genes. Because a total of approximately 500 B-lymphoid clones proliferated in the 96 wells ofeach plate and because 5% of the wells contained anti-Gal, it is likely that approximately 1% of these clones produced anti-Gal. Accordingly, 0.25% of the clones produced, anti-blood group A or antiblood group B antibodies. It should be stressed that not all bands display the same intensity, implying that the growth rate of B-lymphoid clones may vary. Thus, this approach for estimating the number of proliferative clones may be
DISCUSSION
The presence of anti-Gal in humans, apes, and Old World monkeys reflects an evolutionary event estimated to have occurred in ancestral Old World primates less than 30 million years ago, which led to the elimination of a-galactosyl epitope expression and loss of immune tolerance against the a-galactosyl epitope.42 Presently, anti-Gal accounts for as much as 1% of circulating IgG in human serum. Because anti-Gal readily interacts with gastrointestinal bacteria.'*.'-' it may be possible that this natural antibody has a protectivc role against invading microorganisms, a role suggested for natural antibodies. in
The large amount of antiGal produced in humans implies that a considerable proportion of B lymphocytes is involved in the synthesis of this antibody. The proportion of B lymphocytes in blood that are capable of producing anti-Gal could be assessed by studying EBV-transformed B lymphocytes.
We screened approximately 2.000 B-lymphoid clones from each of 20 individuals (because each of the four plates screened per individual, contained on average 500 lymphoid clones). As many as I % of the immortalized B-lymphoid clones produced anti-Gal. This conclusion is based on the observation that 5% of the wells plated with transformed B lymphocytes contained anti-Gal antibodies in the supernatant and that, on average, five lymphoid clones proliferated in each well. The number ofclones per well assayed by limiting dilutions, is consistent with observations of Taub et aI2' in that the rate of EBV immortalization is one in 2,000 B lymphocytes. This frequency of transformation is lower than that reported by Tosato et aI3' who used irradiated T lymphocytes as feeder cells in round bottom wells. Under such conditions the sensitivity of the hemagglutination assay might have been insufficient for the detection of very low concentrations of anti-Gal.
The conclusion of the limiting dilution studies that, on average, five clones proliferate in each well was further supported by the analysis of the IgH gene rearrangement patterns in expanded cultures. This approach, although directly demonstrating the number of clones per well, may not be used as the primary means for assessment of clonality, because in the process of expansion of the proliferating cells some of the clones could theoretically expand faster than others. This may account for the apparent monoclonality observed in some wells and for the differences in band intensity in some cultures. In addition, bands of different clones may occasionally comigrate because of similarity in size. Nevertheless, the finding of only 2 to 10 bands in DNA from proliferating B-lymphoid clones in each well studied, even after long exposure time of the Southern blots to film, supports the assessment obtained in the limiting dilution assays, that the transformed B lymphocytes proliferate in these wells in an oligoclonal rather than polyclonal fashion and that the number of proliferating clones is, on average, five per well.
The observation that as many as 1 % of circulating B lymphocytes are capable of producing anti-Gal antibodies correlates with the findings that anti-Gal constitutes 1% of circulating IgG in human^.^-^ However, this observation is surprising in view of the notion that the repertoire of B lymphocytes encompasses more than 1 O6 different antibody specificitie~.'~~~~~ Many other natural antibodies that have been studied and that display anti-protein, anti-DNA, or anti-phospholipid reactivity are polyreactive (ie, cross-react with various antigenic determinant^),^^^^,^^ and are found in the serum in concentrations 500-to 1,000-fold lower than anti-Gal.'7%'8 The high specificity of anti-Gal for the a-galactosyl epitope sets this natural antibody apart of natural polyreactive antibodies. This high specificity may be a consequence of the lack of electrostatic charges in the a-galactosyl epitope. Because no electrostatic interactions (ie, ionic bonds) participate in the binding of anti-Gal to a-galactosyl epitopes, a precise "fitting" between the antibody and the ligand is required to enable the hydrogen bonds, hydrophobic and Van der Waals forces, to facilitate the interaction. As previously argued by Kabat et charged groups with a given spacing on different antigens may result in cross-reactivity of an antibody with nonrelated antigens. Neutral epitopes devoid of electrostatic charges are unlikely to participate in such cross-reactive interactions. In turn, the lack of ionic bonds may, however, result in an overall lower affinity of anticarbohydrate antibodies, in comparison with the affinity observed in antipeptide antibodies.
The highly restricted specificity of serum anti-Gal and its in vitro produced clones was demonstrated in the present study by their interaction with synthetic a-galactosyl epitopes and with none of the other synthetic oligosaccharides assayed. A similar specificity of serum anti-Gal was also observed by other researchers using synthetic oligosacchar i d e~.~,~, " ,~~
The specificity of anti-Gal clones toward a-galactosyl epitopes was further demonstrated in the ELISA assay, where in vitro produced anti-Gal bound to mouse laminin that contains 50 to 70 a-galactosyl e p i t~p e s~~ but not to bovine fetuin, a glycoprotein that lacks this carbohydrate s t r~c t u r e .~' ,~~ Similarly, anti-Gal clones interacted with CPH but not with paragloboside molecules. The individual anti-Gal clones displayed minor variations in specificity as indicated by the findings that some bound better to a-galactosyl epitopes on a glycoprotein (ie, laminin) and others to glycolipid with this epitope (ie, CPH). This may suggest small differences in the combining sites of the antiGal molecules, which may be affected by the mannosyl units that are present within the core carbohydrate chain of glycoproteins but absent from glycolipids. Variations jn the combining site of anti-Gal were also suggested in our previous study,7 which demonstrated in individuals with blood groups A or 0, the presence of anti-Gal clones capable of interacting with blood group B antigen (ie, a-galactosyl epitopes in which the penultimate galactose is fucosylated). Such clones are absent in the blood of individuals with blood type B or AB. Clonal variations are also suggested in the affinity of anti-Gal clones to rabbit RBC. As derived from their concentration in the supernatants and their agglutinating ability, the end point agglutination of rabbit RBC for clone 8 was at a concentration of 0.2 pg/mL, whereas it was 1.5 pg/mL for clone 2, 2 pg/mL for clone 4, and 0.5 &mL for clone 7. Analogous variations in the fine specificity due to polyclonality of antibody response to the carbohydrate epitope a( 1-6) dextran and corresponding variations the sequences of the involved Ig genes, were previously observed in mice immunized with dextran B512.47, 48 We are currently sequencing the immunoglobulin variable regions of the anti-Gal producing B lymphocytes. The information obtained will help to determine whether such clonal variations reflect differences due to somatic mutations in one set of V, and V, genes or if the various clones use a more diverse repertoire of V, and V, genes. Such studies also may provide information on the relationship between anti-Gal encoding genes, and those ofother natural polyreactive autoantibodies, which usually are encoded by germline genes derived from a restricted number of V, gene fa mi lie^.^^,^' Lymphocytes with the potential for producing anti-blood group A and anti-blood group B antibodies also comprise relatively large populations. The overall frequencies of lymphocytes producing anti-Gal, anti-A, or anti-B antibodies are considerably higher than those expected in view of the antigenic diversity of the immune system. These three natural anticarbohydrate antibodies seem to be produced in response to stimulation by bacterial carbohydrate antig e n~. '~, '~.~' It is possible therefore, that clones producing antibacterial carbohydrate antibodies expand under physiologic conditions to ultimately comprise a significant proportion of circulating B lymphocytes. It is likely that these lymphocytes are part of a large lymphoid population that has the role to produce protective natural antibodies against bacteria of the natural flora.43 The proportion of B lymphocytes capable of producing anti-Gal is twofold to sevenfold higher than that of B lymphocytes capable of producing specific anti-DNA antibodies in patients with systemic lupus erythem a t o s~s .~~*~~ This comparison implies that there is a continFor personal use only. on September 24, 2017. by guest www.bloodjournal.org From uous vigorous immune response for anti-Gal production possibly against antigens of the normal flora in humans. This intensive anti-Gal immune response is further suggested by our previous observations3 that anti-Gal production in humans cannot be eliminated even under a massive immunosuppressive regimen.
Finally, studies on murine immune response to specific haptens have demonstrated a relatively fast turnover rate of B lymphocyte^,^^ accompanied by affinity maturation that is mediated by somatic mutation^.^^-^^ The information on the molecular events occurring in mature B lymphocytes in humans is scarce because of the difficulties involved in cloning normal B lymphocytes capable of producing antibodies against defined haptenic structures. Current studies on the Ig genes encoding for anti-Gal synthesis in B-lymphoid clones isolated from different individuals may add to the information on the molecular aspects of the physiologic immune response to chemically defined antigenic structures in humans.
